Loading stock data…
EVO
$3.09-0.02 (-0.64%)
Market ClosedLast close May 1
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Evotec SE in the Healthcare sector is trading at $3.09. The stock is currently 36% below its 52-week high of $4.80, remaining 8.8% below its 200-day moving average. Technical signals show neutral RSI of 62 and bearish MACD signal, explaining why EVO maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 62) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.09
Potential Upside
5%
Whystock Fair Value$3.24
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.18B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.24
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-19.11%
Volume
Today's trading volume
12,968
Recent News
H.C. Wainwright Initiates Coverage of Evotec (EVO) with a Buy Rating
Evotec SE (NASDAQ:EVO) is one of the 10 Best Penny Stocks to Buy and Hold Under $5. On April 14, 2026, H.C. Wainwright assumed coverage of Evotec SE (NASDAQ:EVO) with a Buy rating and a $7 price target, citing the company’s shift from a legacy asset-heavy integrated model toward a more streamlined and capital-efficient structure. […]
Is It Time To Reassess Evotec (XTRA:EVT) After The Recent 24.5% Share Price Jump
If you are wondering whether Evotec's current share price reflects its underlying value, it helps to start with what the market has been pricing in recently. Over the last week the stock returned 24.5%, with a 29.5% return over 30 days and a 2.1% return year to date, while the 1 year return stands at an 11.8% decline and the 3 and 5 year returns show larger drawdowns of 68.2% and 83.2% respectively. These moves sit against a backdrop of ongoing interest in Evotec as a listed life sciences...
Evotec (XTRA:EVT) Valuation Check After Recent Share Price Rebound
Why Evotec is on investors’ radar today Evotec (XTRA:EVT) has caught attention after a sharp share price move, with the stock up about 23% over the past week and roughly 27% over the past month. This short term strength contrasts with weaker performance over the past 3 months and past year. This has prompted investors to reassess the company’s €5.57 share price against its fundamentals and recent financial results. See our latest analysis for Evotec. The sharp 7 day share price return of...
What Makes Evotec (EVO) Appear so Attractive
Evotec SE (NASDAQ:EVO) is one of the 8 Best Life Sciences Penny Stocks to Buy. On March 10, Evotec SE (NASDAQ:EVO) announced Horizon, the follow-up phase in its multi-stage transformation initiative. The Horizon operating model embodies its evolution in the adoption of a new, focused operating model that comprises three elements, i.e., operation, science, and […]
Evotec (EVO) Q3 2025 Earnings Call Transcript
Christian Wojczewski: Thank you, Volker. Very pleased with the momentum and high speed of our transformation towards better monetizing our technology leadership. This is driven by our D&PD business, where we faced continued softness in the early drug discovery market, leading to 12% revenue decline.